Palisade Bio (PALI) 10-Q 23 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 20, 2021
Document Information [Line Items]
Entity Central Index Key	0001357459
Entity Registrant Name	PALISADE BIO, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-33672
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-2007292
Entity Address, Address Line One	5800 Armada Drive, Suite 210
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92008
City Area Code	858
Local Phone Number	704-4900
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	PALI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,398,698

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 12,653,000	$ 713,000
Accounts receivable	59,000	59,000
Prepaid expenses and other current assets	2,013,000	124,000
Total current assets	14,725,000	896,000
Restricted cash	26,000	26,000
Deferred transaction costs	0	1,817,000
Right-of-use asset	195,000	275,000
Property and equipment, net	3,000	5,000
Total assets	14,949,000	3,019,000
Current liabilities:
Accounts payable	1,406,000	2,537,000
Accrued liabilities	955,000	2,740,000
Accrued compensation and benefits	164,000	1,590,000
Current portion of lease liability	184,000	168,000
Current portion of debt	696,000	578,000
Current portion of related party debt, net	445,000	469,000
Total current liabilities	3,850,000	8,082,000
Warrant liability	20,526,000	1,830,000
Non-current portion of debt	0	94,000
Lease liability, net of current portion	17,000	112,000
Total liabilities	24,393,000	10,118,000
Commitments and contingencies (Note 11)
Stockholders’ deficit:
Common stock, $0.01 par value; 300,000,000 and 6,797,500 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 11,398,698 and 2,774,502 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	114,000	28,000
Additional paid-in capital	94,242,000	51,396,000
Accumulated deficit	(103,802,000)	(68,026,000)
Total stockholders' deficit	(9,444,000)	(16,602,000)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	14,949,000	3,019,000
Series C Preferred Stock [Member]
Current liabilities:
Series C convertible preferred stock, $0.001 par value; 0 and 33,594,625 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 0 and 11,674,131 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively; liquidation preference of $10.4 million as of December 31, 2020	0	9,503,000
Series A Preferred Stock [Member]
Stockholders’ deficit:
Series A convertible preferred stock, 7,000,000 shares authorized, $0.01 par value; 200,000 and 0 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	$ 2,000	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, shares authorized (in shares)	7,000,000
Preferred stock, par value (in dollars per share)	$ 0.01
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	6,797,500
Common stock, shares issued (in shares)	11,398,698	2,774,502
Common stock, shares outstanding (in shares)	11,398,698	2,774,502
Series C Preferred Stock [Member]
Series C convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Series C convertible preferred stock, shares authorized (in shares)	0	33,594,625
Series C convertible preferred stock, shares issued (in shares)	0	11,674,131
Series C convertible preferred stock, shares outstanding (in shares)	0	11,674,131
Series C convertible preferred stock, liquidation preference		$ 10.4
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued (in shares)	200,000	0
Preferred stock, shares outstanding (in shares)	200,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 314	$ 650	$ 1,006	$ 1,902
In-process research and development	30,117	0	30,117	0
General and administrative	2,427	1,191	3,688	2,334
Total operating expenses	32,858	1,841	34,811	4,236
Loss from operations	(32,858)	(1,841)	(34,811)	(4,236)
Other income (expense):
Gain on forgiveness of PPP loan	0	0	279	0
Loss on issuance of secured debt	0	0	(686)	0
Change in fair value of warrant liability	5,133	0	5,175	0
Change in fair value of share liability	73	0	73	0
Interest expense	(655)	(11)	(2,367)	(11)
Other income	16	1	16	12
Loss on issuance of LBS Series 1 Preferred Stock	(1,881)	0	(1,881)	0
Issuance cost of warrants	(1,574)	0	(1,574)	0
Total other income (expense)	1,112	(10)	(965)	1
Net loss	$ (31,746)	$ (1,851)	$ (35,776)	$ (4,235)
Loss per share:
Basic (in dollars per share)	$ (3.59)	$ (0.67)	$ (6.17)	$ (1.53)
Diluted (in dollars per share)	$ (4.10)	$ (0.67)	$ (6.96)	$ (1.53)
Weighted average shares used in computing loss per share:
Basic (in shares)	8,831,517	2,774,296	5,803,010	2,774,237
Diluted (in shares)	8,984,198	2,774,296	5,879,351	2,774,237
Net loss attributable to common stockholders – basic	$ (31,746)	$ (1,851)	$ (35,776)	$ (4,235)
Change in fair value of warrants	(5,119)	0	(5,119)	0
Net loss attributable to common stockholders – diluted	$ (36,865)	$ (1,851)	$ (40,895)	$ (4,235)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]Series C Convertible Preferred Stock [Member]	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]Preferred Stock [Member]	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]Common Stock [Member]	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]Additional Paid-in Capital [Member]	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]Retained Earnings [Member]	Conversion of Senior Secured Debt to LBS Series 1 Preferred Shares [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]Series C Convertible Preferred Stock [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]Preferred Stock [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]Common Stock [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]Additional Paid-in Capital [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]Retained Earnings [Member]	Conversion of LBS Series 1 Preferred Stock to Common Shares Upon Merger [Member]	Conversion of LBS Series C Preferred Shares to Common Shares Upon Merger [Member]Series C Convertible Preferred Stock [Member]	Conversion of LBS Series C Preferred Shares to Common Shares Upon Merger [Member]Common Stock [Member]	Conversion of LBS Series C Preferred Shares to Common Shares Upon Merger [Member]Additional Paid-in Capital [Member]	Conversion of LBS Series C Preferred Shares to Common Shares Upon Merger [Member]Retained Earnings [Member]	Conversion of LBS Series C Preferred Shares to Common Shares Upon Merger [Member]	Series C Convertible Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019																		11,674,131	0	2,774,176
Balance at Dec. 31, 2019																		$ 9,503	$ 0	$ 28	$ 49,344	$ (57,704)	$ (8,332)
Stock-based compensation expense																		0	0	0	487	0	487
Net loss																		$ 0	$ 0	$ 0	0	(2,384)	(2,384)
Balance (in shares) at Mar. 31, 2020																		11,674,131	0	2,774,176
Balance at Mar. 31, 2020																		$ 9,503	$ 0	$ 28	49,831	(60,088)	(10,229)
Balance (in shares) at Dec. 31, 2019																		11,674,131	0	2,774,176
Balance at Dec. 31, 2019																		$ 9,503	$ 0	$ 28	49,344	(57,704)	(8,332)
Net loss																							(4,235)
Conversion of LBS Series C Preferred stock into common stock																							0
Balance (in shares) at Jun. 30, 2020																		11,674,131	0	2,786,163
Balance at Jun. 30, 2020																		$ 9,503	$ 0	$ 28	50,233	(61,939)	(11,678)
Balance (in shares) at Mar. 31, 2020																		11,674,131	0	2,774,176
Balance at Mar. 31, 2020																		$ 9,503	$ 0	$ 28	49,831	(60,088)	(10,229)
Stock-based compensation expense																		0	0	0	393	0	393
Net loss																		$ 0	$ 0	$ 0	0	(1,851)	(1,851)
Issuance of common stock to vendor (in shares)																		0	0	11,987
Issuance of common stock to vendor																		$ 0	$ 0	$ 0	9	0	9
Balance (in shares) at Jun. 30, 2020																		11,674,131	0	2,786,163
Balance at Jun. 30, 2020																		$ 9,503	$ 0	$ 28	50,233	(61,939)	(11,678)
Balance (in shares) at Dec. 31, 2020																		11,674,131	0	2,774,502
Balance at Dec. 31, 2020																		$ 9,503	$ 0	$ 28	51,396	(68,026)	(16,602)
Stock-based compensation expense																		0	0	0	569	0	569
Net loss																		$ 0	$ 0	$ 0	0	(4,030)	(4,030)
Balance (in shares) at Mar. 31, 2021																		11,674,131	0	2,774,502
Balance at Mar. 31, 2021																		$ 9,503	$ 0	$ 28	51,965	(72,056)	(20,063)
Balance (in shares) at Dec. 31, 2020																		11,674,131	0	2,774,502
Balance at Dec. 31, 2020																		$ 9,503	$ 0	$ 28	51,396	(68,026)	(16,602)
Net loss																							(35,776)
Conversion of LBS Series C Preferred stock into common stock																							9,503
Balance (in shares) at Jun. 30, 2021																		0	200,000	11,398,698
Balance at Jun. 30, 2021																		$ 0	$ 2	$ 114	94,242	(103,802)	(9,444)
Balance (in shares) at Mar. 31, 2021																		11,674,131	0	2,774,502
Balance at Mar. 31, 2021																		$ 9,503	$ 0	$ 28	51,965	(72,056)	(20,063)
Stock-based compensation expense																		0	0	0	495	0	495
Net loss																		$ 0		$ 0		(31,746)	(31,746)
Issuance of common stock to vendor (in shares)																		0	0	118,833
Issuance of common stock to vendor																		$ 0	$ 0	$ 1	1,183	0	1,184
Issuance of common stock warrants related to promissory note																		$ 0	$ 0	$ 0	16	0	16
Conversion of convertible securities (in shares)	0	786,957	0
Conversion of convertible securities	$ 0	$ 0	$ 0	$ 2,421	$ 0	$ 2,421
Issuance of LBS Series 1 Preferred shares (in shares)																		0	4,516,611	0
Conversion of stock (in shares)							0	(5,303,568)					(11,674,131)
Conversion of stock							$ 0	$ 0					$ (9,503)
Conversion of stock (in shares)									5,303,568,000					317,420
Conversion of LBS Series C Preferred stock into common stock									$ 53	$ (53)	$ 0	$ 0		$ 3	$ 9,500	$ 0	$ 9,503
Issuance of common shares to former shareholders of Seneca upon Merger (in shares)																		0	0	2,884,375
Issuance of common shares to former shareholders of Seneca upon Merger																		$ 0	$ 0	$ 29	28,699	0	28,728
Acquisition of Seneca Series A Preferred Stock upon Merger (in shares)																		0	200,000	0
Acquisition of Seneca Series A Preferred Stock upon Merger																		$ 0	$ 2	$ 0	0	0	2
Restricted stock units vested upon Merger																		0	0	0	41	0	41
Equity warrant put rights activated upon Merger																		0	0	0	(51)	0	(51)
Expiration of put rights on equity classified warrants																		$ 0	$ 0	$ 0	26	0	26
Balance (in shares) at Jun. 30, 2021																		0	200,000	11,398,698
Balance at Jun. 30, 2021																		$ 0	$ 2	$ 114	$ 94,242	$ (103,802)	$ (9,444)

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net loss	$ (31,746)	$ (1,851)	$ (35,776)	$ (4,235)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			2	1
In-process research and development	30,117	0	30,117	0
Noncash transaction costs shared with Seneca			(135)	0
Noncash lease expense			80	3
Gain on forgiveness of PPP loan	0	0	(279)	0
Accretion of debt discount and non-cash interest expense			2,203	12
Loss on issuance of LBS Series 1 Preferred Stock	1,881	0	1,881	0
Loss on issuance of debt	0	0	686	0
Issuance cost allocated to warrant			1,574	0
Change in fair value of warrant liabilities	(5,133)	0	(5,175)	0
Change in fair value of share liability	(73)	0	(73)	0
Stock-based compensation			1,064	880
Write off of accounts payable			183	0
RSU vesting expense			41	0
Changes in operating assets and liabilities:
Trade and other receivables			25	(53)
Prepaid and other assets			(1,294)	43
Accounts payable and accrued liabilities			(2,499)	998
Accrued compensation			(1,518)	0
Operating lease liabilities			(79)	0
Net cash used in operating activities			(8,972)	(2,351)
Cash flows from investing activities:
Cash acquired in connection with the Merger			3,279	0
Acquisition related costs paid			(2,985)	0
Purchases of property and equipment			0	(6)
Net cash provided by (used in) investing activities			294	(6)
Cash flows from financing activities:
Payments on debt			(285)	0
Proceeds from issuance of debt			1,250	279
Proceeds from issuance of LBS Series 1 Preferred Stock			19,900	0
Redemption of warrants			(99)	0
Payment of debt issuance costs			(148)	0
Net cash provided by financing activities			20,618	279
Net increase (decrease) in cash, cash equivalents and restricted cash			11,940	(2,078)
Cash, cash equivalents and restricted cash, beginning of period			739	3,623
Cash, cash equivalents and restricted cash, ending of period	12,679	1,545	12,679	1,545
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:
Cash and cash equivalents	12,653	1,519	12,653	1,519
Restricted cash	26	26	26	26
Total cash, cash equivalents and restricted cash	$ 12,679	$ 1,545	12,679	1,545
Supplemental disclosure of cash flows:
Interest paid			50	0
Supplemental disclosures of non-cash investing and financing activities:
Transaction costs shared with Seneca			135	0
Acquisition related costs included in accounts payable and accrued liabilities			367	0
Acquisition costs related to stock issuance			1,184	0
Issuance of common stock to former Seneca stockholders			28,728	0
Conversion of LBS Series C Preferred stock into common stock			9,503	0
Net assets acquired in the Merger			2	0
Acquisition related vesting of RSU’s assumed in the Merger			41	0
Acquisition related fair value change in warrant liability assumed in the Merger			$ 51	$ 0

Note 1 - Organization, Business

Note 1 - Organization, Business and Financial Condition	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization, Business and Financial Condition The Merger On April 27, 2021, December 16, 2020, 1, one April 27, 2021, 1 1 6 Unless the context otherwise requires, references to the “Company,” “Palisade,” “Palisade Bio,” the “combined organization,” “we,” “our” or “us” in this report refer to Palisade Bio, Inc. and its subsidiaries after completion of the Merger. In addition, references to “Seneca” or “LBS” refer to these entities prior to the completion of the Merger. Description of Business Palisade Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies to improve the lives of patients affected by a broad range of diseases and conditions triggered by gastrointestinal dysregulation. The Company is on the forefront of elucidating the role the gut plays in driving multiple disease states and conditions inside and outside the gastrointestinal tract. The Company is applying its knowledge and its industry experience to develop oral small-molecule drugs to maintain the integrity of the gut epithelial barrier, microbiome, and gut immune cells to improve acute and chronic Gastrobiome™-mediated outcomes. Palisade’s initial focus is combatting the interruption of GI function (ileus) following major surgery to reduce recovery times and shorten patients’ length of stay in the hospital. The Company’s programs have the potential to prevent the formation of post-operative adhesions, as well as to address the myriad health conditions and complications associated with chronic disruption of the intestinal mucosal barrier. The following Unaudited Condensed Consolidated Financial Statements are representative of LBS’s operations prior to the closing of the merger and the consolidated operations thereafter including the operations of Palisade’s wholly owned and controlled subsidiary located in the People’s Republic of China. All the entities are consolidated in our condensed consolidated financial statements and all intercompany activity has been eliminated. Liquidity and Going Concern The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced losses and negative cash flows from operations since its inception. At June 30, 2021, Historically, the Company has funded its operations primarily through a combination of debt and equity financings. Management’s plans continue to be focused on raising additional capital or other financings, such as potential partnering events of the Company’s existing technology. However, no not 12 one not The Company plans to continue to fund its operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third no may COVID- 19 On January 30, 2020, 19 March 2020, 19 In April 2020, 19 19 not LB1148. 19 may 19 may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation In management’s opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly Palisade’s financial position, results of operations and cash flows. The interim results of operations are not may not 8 December 31, 2020, Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and notes. The most significant estimates in the Company’s financial statements relate to clinical trial accruals and valuation of derivative liabilities and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may may Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment which consists of research and development activities Cash and Cash Equivalents Cash and cash equivalents represent cash available in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three Restricted Cash At each June 30, 2021 December 31, 2020, Deferred Transaction Costs Deferred Transaction Costs consists of the direct and incremental costs incurred by the Company related to the acquisition of assets under the Merger Agreement. These costs represent legal, accounting and other direct costs related to the acquisition of assets under the Merger Agreement. As of June 30, 2021, December 31, 2020, 3, Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may not Property and Equipment, Net Property and equipment, which consist of computers, are stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets (approximately three not Convertible Preferred Stock The Company’s Series C convertible preferred stock has been classified in the balance sheets as temporary equity instead of permanent equity within stockholders’ deficit in the balance sheet, in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities as the stock is conditionally redeemable upon certain change in control events outside of the Company’s control, including the liquidation, sale or transfer of control of the Company. Upon such change in control events the holders of the convertible preferred stock can cause its redemption. The Company did not December 31, 2020 not In connection with the Merger, the Series C Convertible Preferred Stock converted to Common Stock. Fair Value of Financial Instruments The Company’s financial instruments consist principally of cash equivalents, accounts receivable, restricted cash, accounts payable, accrued liabilities, debt and derivative liabilities. The carrying amounts of financial instruments such as cash equivalents, accounts receivable, restricted cash, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s current and non-current debt approximates its fair value due to the market rate of interest. The Company’s derivative financial instruments are carried at fair value based on unobservable market inputs. None Derivative Financial Instruments The Company does not The Company reviews the terms of debt instruments, equity instruments and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may The Company accounts for its common stock warrants and tranche liability in accordance with Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging 815” 815, not Research and Development Costs Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials and contract services. All research and development costs are expensed as incurred. Clinical Trial Expenses Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company’s contract arrangements. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may may Patent Costs Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses. Debt Issuance Costs Debt issuance costs incurred to obtain debt financing are deferred and are amortized over the term of the debt using the effective interest method. Debt issuance costs are recorded as a reduction to the carrying value of the debt and are amortized to interest expense for in the condensed statements of operations. Income Taxes The Company follows the ASC 740, Income Taxes 740 740” 740 not not The Company accounts for uncertain tax positions pursuant to ASC 740, Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur as a reduction of expense. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. Net Loss Per Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series C convertible preferred stock (the "Convertible Preferred Stock"), the Senior Secured Promissory Note Warrants and May 2021 not not Diluted earnings per share is computed using the more dilutive of the "two class method" or the "if converted method." Dilutive earnings per share under the "two class method" is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the participating securities, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares. Dilutive earnings per share under the "if converted method" is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares. Potentially dilutive common shares consist of shares issuable for the Senior Secured Promissory Note Warrants and the May 2021 8 The following table presents the calculation of weighted average shares used to calculate basic and diluted loss per share: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2021 Weighted average shares outstanding 8,831,517 2,774,296 5,803,010 2,774,237 Effect of potentially dilutive common shares from Senior Secured Promissory Note Warrants and the May 2021 Warrants 152,681 - 76,341 - Weighted average shares used in calculating diluted loss per share 8,984,198 2,774,296 5,879,351 2,774,237 The following potentially common shares were excluded from diluted net loss per share because the effects would be anti-dilutive: June 30, 2021 2020 Employee stock options 802,455 796,008 Warrants for common stock 851,168 99,714 Series C convertible preferred stock - 317,420 Series A convertible preferred stock 6,479 - RSU's Outstanding 8,817 - Total 1,668,919 1,213,142 Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss was the same as its reported net loss for all periods presented. Recently Adopted Accounting Pronouncements In November 2017, No. 2016 18, 230 2016 18” 2016 18 December 31, 2018, January 1, 2021, not In December 2019, No. 2019 12, 740 Simplifying the Accounting for Income Taxes 2019 12" 2019 12 December 15, 2020, not 2019 12, January 1, 2021. No. 2019 12 not In May 2021, ASU No. 2021 04, 260 Modifications and Extinguishments (Subtopic 470 50 Stock Compensation (Topic 718 Contracts in Entity s Own Equity (Subtopic 815 40 s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04" December 15, 2021. January 1, 2021 2021 04. 2021 04 second 2021 8 Recently Issued Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses 326 2016 13” 2016 13, November 2019, December 15, 2022 may In August 2020, 2020 06, Debt Debt with Conversion and Other Options 470 20 Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 1 2 3 may December 15, 2023, December 15, 2020, may

Note 3 - Merger Between Seneca

Note 3 - Merger Between Seneca and LBS	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. On December 16, 2020, April 27, 2021, The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Under this method of accounting, LBS was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i) LBS’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) LBS designated a majority of the members of the initial board of directors (5 of 8 total members) of the combined company, (iii) LBS’s senior management holds all key positions in the senior management of the combined company and (iv) the only employees remaining in the combined company are that of LBS employees (all Seneca employees were terminated on the date of Merger). As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the accompanying condensed consolidated financial statements of the Company and the reported operating results prior to the Merger are those of LBS. Pursuant to the terms of the Merger Agreement, each share of LBS common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.02719 shares of Company common stock (the “Exchange Ratio”), such that, immediately following the effective date of the Merger, preexisting LBS equity holders held approximately 74.9% of the capital stock of Seneca outstanding immediately following the Merger, and the equity holders of Seneca immediately before the Merger held approximately 25.1% of the Seneca capital stock outstanding immediately following the Merger. Holders of the Company’s common stock will be entitled to one In accordance with the Merger Agreement, Seneca shareholders retain the right to receive cash payments if certain of the legacy Seneca patents or assets are sold within the 48 months following the Merger close. The contingent value right (“CVR”) payment amount is calculated as 80% of the net proceeds received (i.e., gross proceeds minus selling expenses) with no no Reverse Stock Split and Exchange Ratio On April 27, 2021, 1 not Merger The Merger, which closed on April 27, 2021, Topic 805, not not three six June 30, 2021. The total purchase price paid in the Merger has been allocated to the net assets acquired and liabilities assumed based on their fair values as of the completion of the Merger. The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts). Consideration Asset Allocation Schedule: Purchase Price Consideration: Number of shares of the combined company issued to Seneca's stockholders (i) 2,884,375 Multiplied by the fair value per share of Seneca's common stock (ii) $ 9.96 Total share value consideration $ 28,728 LBS transaction costs $ 4,670 Total purchase price $ 33,398 (i) Represents the actual post reverse stock split effected number of shares of Seneca common stock outstanding immediately prior to the merger. (ii) The purchase price was based on the closing price as reported on the Nasdaq Capital Market on April 27, 2021 ( The allocation of the purchase price is as follows (in thousands): Fair Value of Assets Cash and cash equivalents $ 3,279 Accounts receivables 24 Prepaid and other current assets 1,270 Accounts payable and accrued expenses (927 ) Accrued compensation (165 ) Warrant liabilities, at fair value (200 ) In-process research and development (IPR&D) (1) 30,117 Purchase price $ 33,398 ( 1 not no

Note 4 - Balance Sheet Details

Note 4 - Balance Sheet Details	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	4. Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2021 2020 Accrued accounts payable $ 201 $ 1,018 Accrued clinical trial costs 589 875 Accrued director stipends 85 759 Accrued other 80 88 $ 955 $ 2,740

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. The Company follows ASC 820 10, Fair Value Measurements and Disclosures As a basis for considering such assumptions, a three 1 Level 1: 2 Level 2: 3 Level 3: no The Company has issued warrants that are accounted for as liabilities. These warrants were valued using a Monte Carlo based valuation model. The Monte Carlo valuation technique was utilized because it embodies all the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) that are necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of estimates that may, During 2020, one six zero As of June 30, 2021, zero The second February 1, 2021. second one zero The May 2021 May 20, 2021. May 2021 one zero As of June 30, 2021, May 2021 zero The following table summarizes the activity of the Company’s Level 3 three six June 30, 2021, 2020, Three and six months ended June 30, 2021 Warrant Liability Ending value at December 31, 2020 $ 1,830 Initial fair value at the original issuance date 1,832 Change in fair value during the period (42 ) Settlement of derivative liabilities Ending value at March 31, 2021 $ 3,620 Initial fair value at the original issuance date 21,914 Equity classified warrant put feature activated 51 Change in fair value during the period (5,133 ) Seneca liability classified warrants assumed 200 Expiration of equity classified warrant put feature (27 ) Settlement of derivative liabilities (99 ) Ending value at June 30, 2021 $ 20,526 At June 30, 2021 December 31, 2020, May 2016 August 2017 3 August 2017 June 30, 2021. Additionally, as a result of the Merger, a put feature was activated on certain equity classified warrants associated with the October 2018 second June 30, 2021. May 2021, The (gains) losses resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying unaudited condensed consolidated statements of operations. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may

Note 6 - Debt

Note 6 - Debt	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Debt consisted of the following as of June 30, 2021 December 31, 2020 ( June 30, December 31, 2021 2020 Financing agreements $ 605 $ 22 Unsecured promissory notes 105 231 Related party note 445 510 Senior Secured debt - 1,677 Paycheck Protection Program Loan - 279 Total debt 1,155 2,719 Less: Unamortized debt discounts (14 ) (1,578 ) Total debt, net 1,141 1,141 Less: current portion of debt (1,141 ) (1,047 ) Non-current portion of debt $ - $ 94 Financing Agreements In June October 2020, ten April May 2021, nine ten June 30, 2021 December 31, 2020, Unsecured Promissory Notes December 2019 On December 18, 2019, 2019 “December 2019 December 2019 December 2020. December 2019 five five December 2019 March 19, 2021 June 19, 2021. June 2021. July 2020 On July 9, 2020, “July 2020 no ten 120th November 6, 2020, July 2020 March 6, 2021. No March 6, 2021 , June 6, 2021. May 25, 2021, November 15, 2021 six June 15, 2021 “July 2020 7 Common Stock Warrants July 2020 July 2020 As of June 30, 2021 December 31, 2020, October 2020   On October 16, 2020, ten ten April 14, 2021. May 25, 2021, November 15, 2021 six June 15, 2021 “October 2020 7 Common Stock Warrants October 2020 October 2020 12 As of June 30, 2021 December 31, 2020, Senior Secured Promissory Notes In connection with the transactions contemplated by the Merger, on December 16, 2020, ( 1 The Senior Secured Promissory Notes had a first December 17, 2020 second February 1, 2021 third March 16, 2021 not third first second zero 360 1 Paycheck Protection Program ( PPP ) In April 2020, no one April 2022. ten 8 24 The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not not 19 may On June 5, 2020, 8 24 75 60 two five In January 2021, The following table summarizes future minimum debt payments as of June 30, 2021 ( Fiscal year 2021 $ 553 2022 602 2023 - 2024 and thereafter - Total debt maturities 1,155 Less: debt discounts (14 ) Less: unamortized interest - Total future minimum payments 1,141 Less: current portion of debt (1,141 ) Non-current portion of debt $ -

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. Deficit Classes of Stock As of June 30, 2021, As of December 31, 2020, Series A Convertible Preferred Stock In connection with the Merger, the Company assumed Seneca’s Series A 4.5% Convertible Preferred Stock. Shares of the Series A 4.5% Series C Convertible Preferred Stock On March 8, 2019, two March 8, 2019, August 15, 2019. first second At inception, the Additional Tranche Right met the criteria for liability classification under ASC 480. August 2019 In addition to the Series C issued to the lead investor, LBS issued 475,923 shares of Series C to other investors for net proceeds of $425,000 during 2019. In connection with the Merger, the Series C Convertible Preferred Stock converted to Common Stock. LBS Series 1 In connection with signing the Merger Agreement, LBS, Seneca and the Altium Growth Fund (the “Investor”). entered into a Securities Purchase Agreement (the “Equity SPA”), pursuant to which, among other things, the Investor agreed to invest up to $20.0 million in cash to fund the combined company following the Merger. In return, LBS issued LBS Series 1 8 1 Common Stock Each share of Common Stock shall entitle the holder thereof to one

Note 8 - Common Stock Warrants

Note 8 - Common Stock Warrants	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Common Stock Warrants [Text Block]	8. From time to time, the Company issues warrants to its investors, creditors and various other individuals, as noted above. The Company’s outstanding common stock warrants that are classified as equity warrants are included as a component of stockholder’s equity at the date of grant at the relative fair value at that grant date. Common stock warrants accounted for as liabilities in accordance with ASC 815 five ten June 30, 2021 December 31, 2020, Amendment of Promissory Notes and Issuance of New Warrants In 2020, 5 Debt July 2020 October 2020 On May 25, 2021, November 15, 2021 ( Issuance of Stock and Warrant to Ecoban Securities, LLC ( Ecoban ) In connection with the closing of the Merger and the Pre-Merger Financing, on May 25, 2021, Senior Secured Promissory Note Warrants In connection with the issuance of the Senior Secured Promissory Notes, the Company issued the Investor warrants for the purchase of up to 188,192 shares of the Company’s Common Stock (the Senior Secured Promissory Note Warrants) and identified an investor put right to offset future equity purchases in exchange for settlement of the Senior Secured Promissory Notes. The Senior Secured Promissory Note Warrants had an exercise price of $17.71 per share and expire five April 27, 2026. not 815. February 1, 2021 December 31, 2020, February 1, 2021 December 17, 2020, 5 Debt 815. June 30, 2021, May 2021 On May 20, 2021, “May 2021 May 2021 five May 2021 May 2021 16th, 45th, 90th 135th April 27, 2021. June 30, 2021, May 2021 The May 2021 not 815. May 2021 May 2021 April 27, 2021. May 2021 815. The following table summarizes warrant activity for the six June 30, 2021: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding, December 31, 2020 195,712 21.20 6.60 Granted 94,096 17.72 - Exercised - - - Forfeited, expired or cancelled - - - Warrants outstanding, March 31, 2021 289,808 10.81 6.03 Granted 6,000,621 3.93 - Seneca warrants assumed 749,792 - - Exercised - - - Settled (20,313 ) - - Forfeited, expired or cancelled (6,279 ) - - Warrants outstanding, June 30, 2021 7,013,629 6.07 4.95

Note 9 - Equity Incentive Plans

Note 9 - Equity Incentive Plans	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. In 2013, 2013 “2013 2013 Seneca’s 2019 “2019 June 12, 2019. April 2021, 2019 In April 2021, 2021 “2021 2021 not January 1 ten January 1, 2022 January 1, 2031, December 31st may January 1st June 30, 2021, no Additionally, in connection with the closing of the Merger, no 2013 2019 The following table summarizes stock option activity and related information under the 2013 2021 six June 30, 2021: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 826,769 $ 32.72 6.49 $ 1,541 Granted 59,818 17.72 Exercised - - - Forfeited, expired or cancelled (84,132 ) Outstanding at June 30, 2021 802,455 $ 33.11 6.75 $ - Vested and expected to vest at June 30, 2021 802,455 33.11 6.75 - Exercisable at June 30, 2021 759,743 $ 33.19 6.66 $ - The weighted-average grant date fair value of options granted during the six June 30, 2021 As of June 30, 2021, The allocation of stock-based compensation for all stock awards is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Research and development expense $ 49 $ 150 $ 323 $ 290 General and administrative 446 243 741 590 Total $ 495 $ 393 $ 1,064 $ 880 The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows: June 30, 2021 2020 Expected term (years) 5.0 6.98 Risk-free interest rate 0.88 % 1.20 % Expected dividend yield - - Volatility 76.05 % 80.0 % Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants. Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. Expected term. The expected term represents the period of time that options are expected to be outstanding. As the Company does not RSU s The Company has granted restricted stock units (RSU’s) to certain employees and board members that entitle the holders to receive shares of common stock upon vesting and subject to certain restrictions regarding the exercise of the RSU’s. The grant date fair value of RSU’s is based upon the market price of the underlying common stock on the date of grant. There were 4,000 RSU’s granted in the three June 30, 2021 three June 30, 2021. At June 30, 2021, no June 30, 2021. No three June 30, 2021. Officer Settlement Agreements The Company’s former Chief Development Officer was terminated in February 2021. four seven six June 30, 2021.

Note 10 - License Agreements

Note 10 - License Agreements	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
License Agreements [Text Block]	10. License Agreements with the Regents of the University of California The Company has entered into two In conjunction with the Co-Development and Distribution Agreement with Newsoara, the Company is obligated to pay the Regents royalties for its portion of the sublicense income equal to 30 percent of one third June 30, 2021 December 31, 2020,

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Facility Leases The Company leases office space for its corporate headquarters under a non-cancelable facility operating lease for 4,911 square feet located in Carlsbad, California. In July 2019, “July 2019 three August 1, 2019 July 31, 2022. not three August 1, 2019 July 31, 2022. August 2019, first 12 three first second The July 2019 not The right-of-use asset as defined by ASC 840 June 30, 2021 December 31, 2020, June 30, 2021 December 31, 2020, Office lease deferral of payments concession On April 29, 2020, 19 six October 2020. June 30, 2021, December 31, 2020, Accrued Employee Compensation As of December 31, 2020, December 31, 2020, Legal Proceedings Between January 8 March 3, 2021, No. 1:21 00166 Jan. 8, 2021); No. 1:21 00172 Jan. 8, 2021); No. 1:21 00310 Jan. 13, 2021); No. 1:21 00242 Jan. 15, 2021); No. 1:21 00585 Jan. 22, 2021); No. 1:21 00292 Feb. 25, 2021); No. 1:21 00980 Mar. 1, 2021); No. 1:21 00326 Mar. 2, 2021); No. 1:21 01869 Mar. 3, 2021)) On March 18, 2021, 8 second 2021. From time to time, the Company may no June 30, 2021, may may Indemnification In accordance with the Company’s amended and restated memorandum and articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no may

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Unsecured Related Party Notes The Yuma Regional Medical Center (“YRMC”) is an equity investor in the Company and is considered a related party. As discussed in Note 6, October 16, 2020, May 2021. 6. Director stipends Unpaid cash stipends owed to our directors for their annual board service are recorded on the Company’s condensed consolidated balance sheets within accrued liabilities. These liabilities were $85,000 and $759,000 as of June 30, 2021, December 31, 2020,

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	13. The Company has evaluated subsequent events through the date of issuance of the condensed consolidated financial statements. Effective July 21, 2021 ( “July 2021 May 2021 no July 2021 six five July Private Equity Investment On August 19, 2021, five

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation In management’s opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly Palisade’s financial position, results of operations and cash flows. The interim results of operations are not may not 8 December 31, 2020,
Consolidation, Policy [Policy Text Block]	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and notes. The most significant estimates in the Company’s financial statements relate to clinical trial accruals and valuation of derivative liabilities and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may may
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment which consists of research and development activities
Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents represent cash available in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash At each June 30, 2021 December 31, 2020,
Deferred Charges, Policy [Policy Text Block]	Deferred Transaction Costs Deferred Transaction Costs consists of the direct and incremental costs incurred by the Company related to the acquisition of assets under the Merger Agreement. These costs represent legal, accounting and other direct costs related to the acquisition of assets under the Merger Agreement. As of June 30, 2021, December 31, 2020, 3,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, Net Property and equipment, which consist of computers, are stated at cost less accumulated depreciation. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets (approximately three not
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Convertible Preferred Stock The Company’s Series C convertible preferred stock has been classified in the balance sheets as temporary equity instead of permanent equity within stockholders’ deficit in the balance sheet, in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities as the stock is conditionally redeemable upon certain change in control events outside of the Company’s control, including the liquidation, sale or transfer of control of the Company. Upon such change in control events the holders of the convertible preferred stock can cause its redemption. The Company did not December 31, 2020 not In connection with the Merger, the Series C Convertible Preferred Stock converted to Common Stock.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company’s financial instruments consist principally of cash equivalents, accounts receivable, restricted cash, accounts payable, accrued liabilities, debt and derivative liabilities. The carrying amounts of financial instruments such as cash equivalents, accounts receivable, restricted cash, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s current and non-current debt approximates its fair value due to the market rate of interest. The Company’s derivative financial instruments are carried at fair value based on unobservable market inputs. None
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments The Company does not The Company reviews the terms of debt instruments, equity instruments and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may The Company accounts for its common stock warrants and tranche liability in accordance with Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging 815” 815, not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials and contract services. All research and development costs are expensed as incurred.
Clinical Trial Expenses, Policy [Policy Text Block]	Clinical Trial Expenses Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company’s contract arrangements. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may may
Patent Costs, Policy [Policy Text Block]	Patent Costs Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.
Debt Issuance Costs, Policy [Policy Text Block]	Debt Issuance Costs Debt issuance costs incurred to obtain debt financing are deferred and are amortized over the term of the debt using the effective interest method. Debt issuance costs are recorded as a reduction to the carrying value of the debt and are amortized to interest expense for in the condensed statements of operations.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows the ASC 740, Income Taxes 740 740” 740 not not The Company accounts for uncertain tax positions pursuant to ASC 740,
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur as a reduction of expense. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series C convertible preferred stock (the "Convertible Preferred Stock"), the Senior Secured Promissory Note Warrants and May 2021 not not Diluted earnings per share is computed using the more dilutive of the "two class method" or the "if converted method." Dilutive earnings per share under the "two class method" is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the participating securities, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares. Dilutive earnings per share under the "if converted method" is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares. Potentially dilutive common shares consist of shares issuable for the Senior Secured Promissory Note Warrants and the May 2021 8 The following table presents the calculation of weighted average shares used to calculate basic and diluted loss per share: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2021 Weighted average shares outstanding 8,831,517 2,774,296 5,803,010 2,774,237 Effect of potentially dilutive common shares from Senior Secured Promissory Note Warrants and the May 2021 Warrants 152,681 - 76,341 - Weighted average shares used in calculating diluted loss per share 8,984,198 2,774,296 5,879,351 2,774,237 The following potentially common shares were excluded from diluted net loss per share because the effects would be anti-dilutive: June 30, 2021 2020 Employee stock options 802,455 796,008 Warrants for common stock 851,168 99,714 Series C convertible preferred stock - 317,420 Series A convertible preferred stock 6,479 - RSU's Outstanding 8,817 - Total 1,668,919 1,213,142
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss was the same as its reported net loss for all periods presented.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In November 2017, No. 2016 18, 230 2016 18” 2016 18 December 31, 2018, January 1, 2021, not In December 2019, No. 2019 12, 740 Simplifying the Accounting for Income Taxes 2019 12" 2019 12 December 15, 2020, not 2019 12, January 1, 2021. No. 2019 12 not In May 2021, ASU No. 2021 04, 260 Modifications and Extinguishments (Subtopic 470 50 Stock Compensation (Topic 718 Contracts in Entity s Own Equity (Subtopic 815 40 s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04" December 15, 2021. January 1, 2021 2021 04. 2021 04 second 2021 8 Recently Issued Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses 326 2016 13” 2016 13, November 2019, December 15, 2022 may In August 2020, 2020 06, Debt Debt with Conversion and Other Options 470 20 Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 1 2 3 may December 15, 2023, December 15, 2020, may

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2021 Weighted average shares outstanding 8,831,517 2,774,296 5,803,010 2,774,237 Effect of potentially dilutive common shares from Senior Secured Promissory Note Warrants and the May 2021 Warrants 152,681 - 76,341 - Weighted average shares used in calculating diluted loss per share 8,984,198 2,774,296 5,879,351 2,774,237
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2021 2020 Employee stock options 802,455 796,008 Warrants for common stock 851,168 99,714 Series C convertible preferred stock - 317,420 Series A convertible preferred stock 6,479 - RSU's Outstanding 8,817 - Total 1,668,919 1,213,142

Note 3 - Merger Between Senec_2

Note 3 - Merger Between Seneca and LBS (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Purchase Price Consideration: Number of shares of the combined company issued to Seneca's stockholders (i) 2,884,375 Multiplied by the fair value per share of Seneca's common stock (ii) $ 9.96 Total share value consideration $ 28,728 LBS transaction costs $ 4,670 Total purchase price $ 33,398 Fair Value of Assets Cash and cash equivalents $ 3,279 Accounts receivables 24 Prepaid and other current assets 1,270 Accounts payable and accrued expenses (927 ) Accrued compensation (165 ) Warrant liabilities, at fair value (200 ) In-process research and development (IPR&D) (1) 30,117 Purchase price $ 33,398

Note 4 - Balance Sheet Details

Note 4 - Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2021 2020 Accrued accounts payable $ 201 $ 1,018 Accrued clinical trial costs 589 875 Accrued director stipends 85 759 Accrued other 80 88 $ 955 $ 2,740

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three and six months ended June 30, 2021 Warrant Liability Ending value at December 31, 2020 $ 1,830 Initial fair value at the original issuance date 1,832 Change in fair value during the period (42 ) Settlement of derivative liabilities Ending value at March 31, 2021 $ 3,620 Initial fair value at the original issuance date 21,914 Equity classified warrant put feature activated 51 Change in fair value during the period (5,133 ) Seneca liability classified warrants assumed 200 Expiration of equity classified warrant put feature (27 ) Settlement of derivative liabilities (99 ) Ending value at June 30, 2021 $ 20,526

Note 6 - Debt (Tables)

Note 6 - Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Debt [Table Text Block]	June 30, December 31, 2021 2020 Financing agreements $ 605 $ 22 Unsecured promissory notes 105 231 Related party note 445 510 Senior Secured debt - 1,677 Paycheck Protection Program Loan - 279 Total debt 1,155 2,719 Less: Unamortized debt discounts (14 ) (1,578 ) Total debt, net 1,141 1,141 Less: current portion of debt (1,141 ) (1,047 ) Non-current portion of debt $ - $ 94
Schedule of Maturities of Long-term Debt [Table Text Block]	Fiscal year 2021 $ 553 2022 602 2023 - 2024 and thereafter - Total debt maturities 1,155 Less: debt discounts (14 ) Less: unamortized interest - Total future minimum payments 1,141 Less: current portion of debt (1,141 ) Non-current portion of debt $ -

Note 8 - Common Stock Warrants

Note 8 - Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding, December 31, 2020 195,712 21.20 6.60 Granted 94,096 17.72 - Exercised - - - Forfeited, expired or cancelled - - - Warrants outstanding, March 31, 2021 289,808 10.81 6.03 Granted 6,000,621 3.93 - Seneca warrants assumed 749,792 - - Exercised - - - Settled (20,313 ) - - Forfeited, expired or cancelled (6,279 ) - - Warrants outstanding, June 30, 2021 7,013,629 6.07 4.95

Note 9 - Equity Incentive Pla_2

Note 9 - Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 826,769 $ 32.72 6.49 $ 1,541 Granted 59,818 17.72 Exercised - - - Forfeited, expired or cancelled (84,132 ) Outstanding at June 30, 2021 802,455 $ 33.11 6.75 $ - Vested and expected to vest at June 30, 2021 802,455 33.11 6.75 - Exercisable at June 30, 2021 759,743 $ 33.19 6.66 $ -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Research and development expense $ 49 $ 150 $ 323 $ 290 General and administrative 446 243 741 590 Total $ 495 $ 393 $ 1,064 $ 880
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	June 30, 2021 2020 Expected term (years) 5.0 6.98 Risk-free interest rate 0.88 % 1.20 % Expected dividend yield - - Volatility 76.05 % 80.0 %

Note 1 - Organization, Busine_2

Note 1 - Organization, Business and Financial Condition (Details Textual) $ in Thousands	Apr. 27, 2021	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance		$ (103,802)	$ (68,026)
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 12,653	$ 713	$ 1,519
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6
Merger Agreement with Leading Biosciences, Inc. [Member]
Merger Agreement, Exchange Ratio	0.02719

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Number of Operating Segments	1
Restricted Cash, Noncurrent	$ 26,000	$ 26,000
Deferred Merger Transaction Costs	$ 0	$ 1,817,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Calculation of Weighted Average Shares Used to Calculate Basic and Diluted Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Weighted average shares outstanding (in shares)	8,831,517	2,774,296	5,803,010	2,774,237
Effect of potentially dilutive common shares from Senior Secured Promissory Note Warrants and the May 2021 Warrants (in shares)	152,681	0	76,341	0
Weighted average shares used in calculating diluted loss per share (in shares)	8,984,198	2,774,296	5,879,351	2,774,237

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Anti-dilutive securities (in shares)	1,668,919	1,213,142
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	802,455	796,008
Warrant [Member]
Anti-dilutive securities (in shares)	851,168	99,714
Series C Convertible Preferred Stock [Member]
Anti-dilutive securities (in shares)	0	317,420
Series A Convertible Preferred Stock[Member]
Anti-dilutive securities (in shares)	6,479	0
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	8,817	0

Note 3 - Merger Between Senec_3

Note 3 - Merger Between Seneca and LBS (Details Textual)	Apr. 27, 2021USD ($)	Jun. 30, 2021
Number of Directors	8
Number of Votes Per Share of Common Stock		1
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6
Merger Agreement with Leading Biosciences, Inc. [Member]
Merger Agreement, Exchange Ratio	0.02719
Merger Agreement, Percentage of the Acquiree's Capital Stock Held by Acquirer's Equity Holders Immediately Following Merger	74.90%
Merger Agreement, Percentage of the Acquiree's Capital Stock Held by Acquiree's Equity Holders Immediately Following Merger	25.10%
Number of Votes Per Share of Common Stock	1
Business Combination, Retention of the Right to Receive Cash Payments for Legacy Patents, Condition, Period of Sale (Month)	48 months
Business Combination, Cash Payments to Acquiree's Shareholders for Sale of Legacy Patents, Percentage of Net Proceeds Received	80.00%
Business Combination, CVR Payment Associated with Legacy Patents, Net Proceeds Threshold	$ 300,000
LBS [Member]
Number of Directors	5

Note 3 - Merger Between Senec_4

Note 3 - Merger Between Seneca and LBS - Consideration Asset Allocation and Purchase Price Allocation (Details) - Merger Agreement with Leading Biosciences, Inc. [Member] $ / shares in Units, $ in Thousands	Apr. 27, 2021USD ($)$ / sharesshares
Number of shares of the combined company issued to Seneca's stockholders (i) (in shares) | shares	2,884,375	[1]
Multiplied by the fair value per share of Seneca's common stock (in dollars per share) | $ / shares	$ 9.96	[2]
Total share value consideration	$ 28,728
LBS transaction costs	4,670
Total purchase price	33,398
Cash and cash equivalents	3,279
Accounts receivables	24
Prepaid and other current assets	1,270
Accounts payable and accrued expenses	(927)
Accrued compensation	(165)
Warrant liabilities, at fair value	(200)
In-process research and development (IPR&D)	30,117	[3]
Purchase price	$ 33,398
[1]	Represents the actual post reverse stock split effected number of shares of Seneca common stock, Seneca preferred stock convertible to common stock, Seneca RSUs, and Seneca Warrants outstanding immediately prior to the merger.
[2]	The purchase price was based on the closing price as reported on the Nasdaq Capital Market on April 27, 2021 (i.e., the Merger close date).
[3]	Represents the research and development projects of Seneca which were in-process, but not yet completed as of the date of the acquisition. Current accounting standards require that the fair value of IPR&D projects acquired in an asset acquisition with no alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date.

Note 4 - Balance Sheet Detail_2

Note 4 - Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accrued accounts payable	$ 201	$ 1,018
Accrued clinical trial costs	589	875
Accrued director stipends	85	759
Accrued other	80	88
Accrued Liabilities, Current, Total	$ 955	$ 2,740

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) $ in Thousands	3 Months Ended
	Jun. 30, 2021USD ($)shares	May 25, 2021USD ($)	Feb. 01, 2021USD ($)	Dec. 31, 2020USD ($)
Derivative Liability, Noncurrent	$ 20,526			$ 1,830
Senior Secured Promissory Note Warrants [Member]
Derivative Liability, Noncurrent			$ 1,800	$ 1,900
Senior Secured Promissory Note Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	17.71		17.71	17.71
Senior Secured Promissory Note Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.99		0.88	0.87
Senior Secured Promissory Note Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0090		0.0050	0.005
Senior Secured Promissory Note Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.4		5.8	6
Senior Secured Promissory Note Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0		0	0
The Equity Warrant [Member]
Derivative Liability, Noncurrent		$ 21,900
The Equity Warrant [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	4.12	10.15
The Equity Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.99	0.91
The Equity Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0094	0.01
The Equity Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.4	5.6
The Equity Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Warrants Issued in Connection with May 2016 and August 2017 Offerings [Member]
Class of Warrant or Right, Put Feature Settled (in shares) | shares	7,813
Warrants Associated with the October 2018 Offering [Member]
Class of Warrant or Right, Put Feature Settled (in shares) | shares	12,500

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details) - Stock Purchase Warrants [Member] - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Balance	$ 3,620	$ 1,830
Initial fair value at the original issuance date	21,914	1,832
Change in fair value during the period	(5,133)	(42)
Equity classified warrant put feature activated	51
Seneca liability classified warrants assumed	200
Expiration of equity classified warrant put feature	(27)
Settlement of derivative liabilities	(99)
Balance	$ 20,526	$ 3,620

Note 6 - Debt (Details Textual)

Note 6 - Debt (Details Textual) - USD ($)	May 25, 2021	Feb. 01, 2021	Dec. 17, 2020	Dec. 16, 2020	Nov. 06, 2020	Oct. 16, 2020	Jul. 09, 2020	Dec. 18, 2019	May 31, 2021	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Oct. 01, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Payments of Debt Issuance Costs																$ 148,000	$ 0
Interest Paid, Excluding Capitalized Interest, Operating Activities																50,000	0
Loss on Issuance of Secured Debt													$ 0	$ 0		686,000	0
Gain (Loss) on Extinguishment of Debt, Total													0	$ 0		279,000	$ 0
Altium Growth Fund, LP [Member] | Senior Secured Promissory Note Warrants, First Closing [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		94,096
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 17.71
Altium Growth Fund, LP [Member] | Senior Secured Promissory Note Warrants, Second Closing [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			94,096
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 17.71
Original Financing Agreements [Member]
Debt Instrument, Interest Rate, Stated Percentage															8.35%
Debt Instrument, Term (Month)															10 months
Additional Financing Agreements One [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.35%	3.60%
Additional Financing Agreements Two [Member]
Debt Instrument, Term (Month)									10 months	9 months
Financing Agreements [Member]
Secured Debt, Total													605,000			605,000		$ 22,000
The December 2019 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Debt Instrument, Face Amount								$ 100,000
Debt Instrument, Early Due Date, Revenue or Gross Financing Proceeds Threshold								$ 5,000,000
July 2020 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Debt Instrument, Term (Month)							120 days
Debt Instrument, Face Amount							$ 125,000
Debt Instrument, Original Issue Discount Percentage							20.00%
Payments of Debt Issuance Costs							$ 0
Debt Instrument, Early Due Date, Gross Equity Proceeds Threshold							$ 1,250,000
Debt Instrument, Renewal Term (Day)	6 months				120 days
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 4,000
Debt Instrument, Periodic Payment, Total	$ 21,445
Unsecured Debt, Total													105,000			105,000		126,000
October 2020 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Debt Instrument, Term (Month)						180 days
Debt Instrument, Face Amount						$ 500,000
Debt Instrument, Original Issue Discount Percentage						10.00%
Debt Instrument, Renewal Term (Day)	6 months
Debt Instrument, Periodic Payment, Total	$ 90,901
Unsecured Debt, Total													$ 445,000			$ 445,000		$ 510,000
Senior Secured Promissory Notes [Member] | Altium Growth Fund, LP [Member]
Debt Instrument, Interest Rate, Stated Percentage													15.00%			15.00%
Securities Purchase Agreement, Maximum Borrowing Capacity				$ 5,000,000
Securities Purchase Agreement, Aggregate Purchase Price				3,750,000
Securities Purchase Agreement, Aggregate Purchase Price, Original Issue Discount				1,250,000
Proceeds from Issuance of Debt		$ 1,700,000	$ 1,700,000
Loss on Issuance of Secured Debt		$ 700,000	$ 800,000
Senior Secured Promissory Notes [Member] | Altium Growth Fund, LP [Member] | Series 1 Preferred Stock of LBS [Member]
Securities Purchase Agreement, Amount Agreed By the Investor to Be Invested in Cash Immediately Prior to merger in Exchange for Preferred Stock				$ 20,000,000
Paycheck Protection Program, CARES Act [Member]
Payments of Debt Issuance Costs												$ 0
Proceeds from Issuance of Long-term Debt, Total												$ 279,000
Gain (Loss) on Extinguishment of Debt, Total											$ 279,000

Note 6 - Debt - Summary of Debt

Note 6 - Debt - Summary of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Total debt	$ 1,155	$ 2,719
Less: debt discounts	(14)	(1,578)
Total debt, net	1,141	1,141
Less: current portion of debt	(1,141)	(1,047)
Non-current portion of debt	0	94
Unsecured Debt [Member]
Total debt	105	231
Financing Agreements [Member]
Total debt	605	22
Related Party Note [Member]
Total debt	445	510
Senior Secured Promissory Notes [Member]
Total debt	0	1,677
Paycheck Protection Program, CARES Act [Member]
Total debt	$ 0	$ 279

Note 6 - Debt - Summary of Futu

Note 6 - Debt - Summary of Future Minimum Debt Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
2021	$ 553
2022	602
2023	0
2024 and thereafter	0
Total debt maturities	1,155	$ 2,719
Less: debt discounts	(14)	(1,578)
Less: unamortized interest	0
Total future minimum payments	1,141	1,141
Less: current portion of debt	(1,141)	(1,047)
Non-current portion of debt	$ 0	$ 94

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Details Textual)	Apr. 27, 2021USD ($)$ / shares	Aug. 15, 2019$ / sharesshares	Mar. 08, 2019USD ($)$ / sharesshares	Jun. 30, 2021$ / sharesshares	Mar. 31, 2021shares	Aug. 15, 2019USD ($)$ / shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Common Stock, Shares Authorized (in shares)				300,000,000			300,000,000			6,797,500
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.01			$ 0.01			$ 0.01
Preferred Stock, Shares Authorized (in shares)				7,000,000			7,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.01			$ 0.01
Class of Warrant or Right, Issued During Period (in shares)				6,000,621	94,096
Proceeds from Issuance of Preferred Stock and Preference Stock | $							$ 19,900,000	$ 0
Number of Votes Per Share of Common Stock				1			1
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 4,695.60			$ 4,695.60
Series A 4.5% Convertible Preferred Stock [Member] | Private Placement [Member]
Preferred Stock, Dividend Rate, Percentage							4.50%
Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)				6,479			6,479
LBS [Member]
Common Stock, Shares Authorized (in shares)										6,797,500
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares										$ 0.01
Preferred Stock, Shares Authorized (in shares)										33,594,625
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares										$ 0.001
LBS [Member] | Lead Investor [Member] | Warrants Associated with Series C Convertible Preferred Stock, First Closing [Member]
Class of Warrant or Right, Issued During Period (in shares)			40,785
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 41.19
LBS [Member] | Lead Investor [Member] | Warrants Associated with Series C Convertible Preferred Stock, Second Closing [Member]
Class of Warrant or Right, Issued During Period (in shares)		13,595
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 41.19				$ 41.19
LBS [Member] | Investors Other than the Lead Investor [Member] | Warrants Associated with Series C Convertible Preferred Stock [Member]
Class of Warrant or Right, Issued During Period (in shares)									951
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 41.19
LBS [Member] | Series C Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)										33,594,625
LBS [Member] | Series C Preferred Stock [Member] | Lead Investor [Member]
Preferred Stock, Subscription Agreement, Maximum Amount | $			$ 30,000,000
Proceeds from Issuance of Previously Subscribed Preferred Stock, Gross | $						$ 10,000,000
Issuance of Previously Subscribed Preferred Stock, Issuance Costs Paid | $						215,000
Proceeds from Issuance of Previously Subscribed Preferred Stock, Net | $						$ 9,800,000
Stock Issued During Period, Shares, New Issues (in shares)			8,398,656
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.893
LBS [Member] | Series C Preferred Stock [Member] | Investors Other than the Lead Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)									475,923
Proceeds from Issuance of Preferred Stock and Preference Stock | $									$ 425,000
LBS [Member] | Series C Preferred Stock [Member] | Shares Subscribed, Additional Tranche Right [Member] | Lead Investor [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.893
Preferred Stock, Shares Subscribed but Unissued (in shares)			2,799,552
Liability for Right of Investor to Purchase Shares | $			$ 79,000
LBS [Member] | Series 1 Preferred Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 17.71
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 19,900,000
Gain (Loss) on Issuance of Preferred Stock | $	(1,900,000)
Payments of Stock Issuance Costs | $	1,600,000
LBS [Member] | Series 1 Preferred Stock [Member] | Maximum [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 20,000,000

Note 8 - Common Stock Warrant_2

Note 8 - Common Stock Warrants (Details Textual) - USD ($)	May 25, 2021	Apr. 27, 2021	Feb. 01, 2021	Dec. 17, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	May 20, 2021	Dec. 31, 2020
Warrants and Rights Outstanding					$ 7,013,629		$ 7,013,629			$ 195,712
Loss on Issuance of Secured Debt					$ 0	$ 0	$ 686,000	$ 0
Ecoban Shares [Member]
Stock Issued During Period, Shares, New Issues (in shares)	118,833
Warrants Converted from Old Warrants Upon Merger [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 26.84
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,904
New Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6
Warrants and Rights Outstanding	$ 16,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	8,000
Ecoban Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 17.72
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	18,353
Senior Secured Promissory Note Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 3.88		$ 3.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					858,892		858,892
Senior Secured Promissory Note Warrants [Member] | Altium Growth Fund, LP [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 17.71
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants and Rights Outstanding			$ 1,800,000							$ 1,900,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			188,192
The Equity Warrant [Member] | Altium Growth Fund, LP [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 3.88		$ 3.88		$ 4.70
Warrants and Rights Outstanding, Term (Year)									5 years
Warrants and Rights Outstanding									$ 21,900,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					5,303,568		5,303,568		4,995,893
Loss on Issuance of Warrant		$ 1,900,000
Senior Secured Promissory Notes [Member] | Altium Growth Fund, LP [Member]
Debt Instrument, Interest Rate, Stated Percentage					15.00%		15.00%
Loss on Issuance of Secured Debt			$ 700,000	$ 800,000
LBS [Member] | Old Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 0.73
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										70,000
LBS [Member] | July 2020 and October 2020 Unsecured Promissory Notes [Member]
Debt Instrument, Face Amount										$ 600,000
Debt Instrument, Interest Rate, Stated Percentage										10.00%
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 3.88		$ 3.88
Warrants and Rights Outstanding, Term (Year)					5 years		5 years
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 4,695.60		$ 4,695.60
Warrants and Rights Outstanding, Term (Year)					10 years		10 years

Note 8 - Common Stock Warrant_3

Note 8 - Common Stock Warrants - Summary of Warrant Activity (Details) - $ / shares	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Warrants outstanding, balance (in shares)	289,808	195,712
Warrants outstanding, weighted average exercise price (in dollars per share)	$ 6.07	$ 10.81	$ 21.20
Warrants outstanding, December 31, 2020 (Year)	4 years 11 months 12 days	6 years 10 days	6 years 7 months 6 days
Class of Warrant or Right, Issued During Period (in shares)	6,000,621	94,096
Granted, weighted average exercise price (in dollars per share)	$ 3.93	$ 17.72
Exercised (in shares)	0	0
Forfeited, expired or cancelled (in shares)	(6,279)	0
Seneca warrants assumed (in shares)	749,792
Settled (in shares)	(20,313)
Warrants outstanding, balance (in shares)	7,013,629	289,808	195,712

Note 9 - Equity Incentive Pla_3

Note 9 - Equity Incentive Plans (Details Textual) - USD ($)	Apr. 27, 2021	Feb. 28, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					59,818
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 0.15
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 600,000	$ 600,000	$ 600,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 4 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%	0.00%
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%
Share-based Payment Arrangement, Option [Member] | Former Chief Development Officer [Member]
Share-based Payment Arrangement, Period by Which Vesting is Accelerated (Year)		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		7 years
Share-based Payment Arrangement, Option [Member] | Former Chief Development Officer [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Accelerated Cost					$ 225,000
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				4,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 10.14
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 41,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)			8,817	8,817	8,817
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share)			$ 9.79	$ 9.79	$ 9.79
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding			$ 36,000	$ 36,000	$ 36,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in shares)				0
The 2021 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,502,583
Common Stock, Capital Shares Reserved for Future Issuance, Period of Yearly Increase (Year)	10 years
Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase, Percentage	1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			0
The 2013 Plan and the 2019 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	0

Note 9 - Equity Incentive Pla_4

Note 9 - Equity Incentive Plans - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Options Outstanding (in shares) | shares	826,769
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 32.72
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 9 months	6 years 5 months 26 days
Options Outstanding, Aggregate Intrinsic Value | $	$ 0	$ 1,541
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares	59,818
Options Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 17.72
Options Exercised (in shares) | shares	0
Options Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0
Options Forfeited, expired or cancelled (in shares) | shares	(84,132)
Options Forfeited, expired or cancelled, Weighted Average Exercise Price (in dollars per share) | $ / shares
Options Outstanding (in shares) | shares	802,455	826,769
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.11	$ 32.72
Options Vested and expected to vest (in shares) | shares	802,455
Options Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.11
Options Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)	6 years 9 months
Options Vested and expected to vest, Aggregate Intrinsic Value | $	$ 0
Options Exercisable (in shares) | shares	759,743
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.19
Options Exercisable, Weighted Average Remaining Contractual Life (Year)	6 years 7 months 28 days
Options Exercisable, Aggregate Intrinsic Value | $	$ 0

Note 9 - Equity Incentive Pla_5

Note 9 - Equity Incentive Plans - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based compensation expense	$ 495	$ 393	$ 1,064	$ 880
Research and Development Expense [Member]
Share-based compensation expense	49	150	323	290
General and Administrative Expense [Member]
Share-based compensation expense	$ 446	$ 243	$ 741	$ 590

Note 9 - Equity Incentive Pla_6

Note 9 - Equity Incentive Plans - Fair Value Assumptions for Stock Options (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Expected term (Year)	5 years	6 years 11 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Volatility	76.05%	80.00%
Minimum [Member]
Risk-free interest rate	0.88%	1.20%

Note 10 - License Agreements (D

Note 10 - License Agreements (Details Textual) - License Agreements with the Regents of the University of California [Member]	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Number of License Agreements	2
Royalty Rate, Portion of Sublicense Income to Be Paid, Percentage of One-third of Upfront Payment and Milestone Payment Received	30.00%
Accrued Royalties, Current	$ 104,000	$ 125,000

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	Mar. 18, 2021	Apr. 29, 2020	Aug. 01, 2019USD ($)	Jun. 30, 2021USD ($)ft²	Mar. 03, 2021	Dec. 31, 2020USD ($)
Operating Lease, Right-of-Use Asset				$ 195,000		$ 275,000
Operating Lease, Liability, Total				201,000		280,000
Rent Deferral Agreement Related to the COVID-19 Pandemic, Proration of Deferred Balance, Period (Month)		6 months
Rent Deferral Agreement Related to the COVID-19 Pandemic, Deferred Balance				0		87,000
Accrual for Suspended Salary Benefits and Bonuses, to Be Paid Upon Closing of Merger						$ 1,100,000
Legal Proceedings Related to the Merger [Member]
Loss Contingency, Pending Claims, Number, Ending Balance					9
Loss Contingency, Claims Dismissed, Number	9
Litigation Settlement, Amount Awarded to Other Party				$ 216,000
Office Space Lease for Corporate Headquarters in Carlsbad, CA [Member]
Area of Real Estate Property (Square Foot) | ft²				4,911
July 2019 Headquarter Lease [Member]
Lessee, Operating Lease, Term of Contract (Year)			3 years
Lessee, Operating Lease, Renewal Term (Month)			36 months
Lease Monthly Payment			$ 16,000
Operating Lease, Contractual Monthly Lease Payments, Yearly Escalation Rate			3.00%

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Oct. 16, 2020
Due to Related Parties, Total	$ 85,000	$ 759,000
October 2020 Note [Member]
Debt Instrument, Face Amount			$ 500,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Aug. 01, 2021	Jul. 21, 2021	Jun. 30, 2021
Subsequent Event [Member] | Private Equity [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 3.45
Stock Issued During Period, Value, New Issues	$ 5.2
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 4,695.60
Warrants and Rights Outstanding, Term (Year)			10 years
July Warrant [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 3.631
Warrants and Rights Outstanding, Term (Year)		5 years
July Warrant [Member] | Maximum [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1,100,000
First Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			5,303,568
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.88
Second Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			858,892
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.88
Private Warrant [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	377,474
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.45
Warrants and Rights Outstanding, Term (Year)	5 years
Third Investor Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.88